Using fenofibrate to protect kidney function in type 1 diabetes
A pilot study of fenofibrate to prevent kidney function loss in type 1 diabetes
This study is looking at whether the medication fenofibrate can help protect kidney function in people with type 1 diabetes who are starting to have kidney problems, and we're inviting 40 participants to see if it can make a difference in their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Joslin Diabetes Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10675516 on NIH RePORTER |
What this research studies
This research investigates the potential of fenofibrate, a generic medication, to prevent kidney function loss in individuals with type 1 diabetes who are at risk of developing diabetic kidney disease. The study aims to enroll 40 participants with early-to-moderate kidney disease to evaluate how well fenofibrate can slow the decline of kidney function. By focusing on patients early in the disease process, the research seeks to provide timely intervention that could improve long-term health outcomes. Participants will be recruited from two academic centers within a consortium dedicated to this important health issue.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type 1 diabetes who have early-to-moderate diabetic kidney disease and are at high risk for end-stage kidney disease.
Not a fit: Patients with type 1 diabetes who do not have any signs of kidney disease or those with advanced kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, cost-effective treatment option for preserving kidney function in patients with type 1 diabetes.
How similar studies have performed: Previous studies have suggested that fenofibrate may have protective effects on kidney function in type 2 diabetes, but this approach in type 1 diabetes is novel and requires further investigation.
Where this research is happening
Boston, United States
- Joslin Diabetes Center — Boston, United States (Active)
Researchers
- Principal investigator: Doria, Alessandro — Joslin Diabetes Center
- Study coordinator: Doria, Alessandro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.